Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 4 | Genetic Vaccines and Therapy

Figure 4

From: Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer

Figure 4

Effect of dsRNA-EGFR on chemosensitivity of NSCLC cells to cisplatin. Cells were transfected with siRNA, then exposed to various doses of cisplatin for 48 h and viability was accessed. The percentage of cell growth was calculated by comparison of the A490 reading from treated versus control cells. The IC50 value of A549 (upper) cells to cisplatin in control group, transfection reagent control, unrelated dsRNA group and dsRNA-EGFR group was 2.67 μg/ml, 2.30 μg/ml, 2.19 μg/ml and 0.50 μg/ml respectively. The IC50 value of SPC-A1 cells to cisplatin (lower) was 3.67 μg/ml, 3.11 μg/ml, 3.07 μg/ml and 0.43 μg/ml respectively.

Back to article page